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Human  lung  tissue  passively sensitized with  homologous  IgE  antibody  releases 
the chemical mediators histamine, slow reacting substance of anaphylaxis (SRS-A)' 
(1-3), and eosinophil chemotactic factor of anaphylaxis (ECF-A)  (4)  upon exposure 
to  specific antigen. Previous studies  (3,  5)  have  demonstrated that  this reaction is 
modulated  by  agents  capable  of  affecting  tissue  levels  of  cyclic  adenosine  3',5'- 
monophosphate  (cyclic  AMP).  Beta  adrenergic  stimulation  produces  measurable 
increases in tissue levels of cyclic AMP and concomitant inhibition of mediator release; 
both effects are prevented by beta adrenergic blockage. In contrast, alpha adrenergic 
stimulation is associated with decreases in tissue levels of cyclic AMP and enhance- 
ment of mediator release. The inverse relationship between the tissue levels of cyclic 
AMP and the quantity of mediators released suggests that the changes occurring in 
the cyclic AMP  levels of  the  total cell population of  intact lung  fragments  reflect 
comparable changes in the subpopulation of target cells involved in mediator release 
and  that  these target cells possess adrenergic receptor sites of  the  beta  and  alpha 
prototype. 
In order to define further the nature of the pharmacological receptors present 
on the target cells in human lung tissue, a  study was initiated to determine if 
cholinergic receptors were also functionally present. The results obtained reveal 
a  cholinergic mechanism  of enhancement  and  confirm and  extend  the studies 
of  alpha  adrenergic  enhancement  of  the  IgE-mediated  release  of  histamine 
and SRS-A from human lung tissue in vitro. 
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Materials and Methods 
Acetylcholine,  carbamylcholine  chloride,  DL-norepinephrine  hydrochloride,  L-phenyl- 
ephrine  hydrochloride,  adenosine  3',5~-cyclic  monophosphorie  acid,  and  atropine  sulfate 
were obtained from Sigma Chemical Co. (St. Louis, Mo.). Propranolol hydrochloride (Inderal, 
Ayerst  Laboratories,  New  York),  antigen  E  (Abbott  Laboratories,  North  Chicago,  Ill.), 
Ns,O2-dibutyryl  cyclic AMP  (Calbiochem,  San  Diego,  Calif.),  cyclic  (83H)  AMP  (14.2 
#Ci/mmole) and (8-14C) adenine (50 #Ci/mmole) (Schwarz/Mann Div., Becton, Dickinson & 
Co., Orangeburg,  N.Y.), Dowex 50  (200-400  mesh)  H+  form (Bio-Rad Laboratories, Rich- 
mond,  Calif.),  1,4-bis[2-(5-phenyloxazolyI)]benzene  (POPOP)  and  2,5-diphenyloxazole 
(PPO)  (Packard Instrument Co. Inc., Downers Grove, II1.), and 24-mm cellulose ester filters 
(0.45/z)  (Millipore Corp., Bedford, Mass.)  were all supplied as noted.  Dr. Lionel Simon of 
ICN Nuclear Acid Research Institute  (ICN Corp., Irvine, Calif.) kindly supplied 8-bromo- 
cyclic 3 r, 5'-guanosine monophosphate (8-bromo-cyclic GMP). 
Preparation of Human  Lung  Tissue for the A ntigen-Induced Release of Mediators.--Human 
lung tissue obtained at the time of surgery was prepared for the antigen-induced release of 
mediators as previously described  (3). The lung tissue was dissected free of pleura, bronchi, 
and large blood vessels; fragmented, washed, and replicated into 200-rag  samples; sensitized 
by incubation in  the serum  of either patient  E.W.  (3)  or S.A.G.  (IgE level, 250  m/zg/ml) 
for 2 hr at 37°C or for 18 hr at room temperature; and washed free of serum and placed in 
Tyrode's buffer containing the agent(s) under study. The sensitized fragments were challenged 
3 min later with antigen E  (0.2 #g/ml), unless specified  otherwise in the text, and the hista- 
mine and  SRS-A released  into  the  diffusate were quantitated  by  bioassay on  the isolated 
guinea pig ileum. Residual tissue histamine was extracted from the lung fragments by boiling 
for 8 min. 
All drugs were prepared in Tyrode's buffer just before use, and at the concentrations studied 
did not interfere with the bioassay of either histamine or SRS-A and did not induce a non- 
specific release of these mediators in the absence of antigen challenge.  The concentrations of 
histamine or SRS-A released from the sensitized tissues  by antigen challenge in the absence 
of any drugs were taken as 100%  and  the per cent inhibition or enhancement of the release 
of these mediators in the presence of each agent was calculated on that basis. 
Cyclic AMP Assays.--Cyclic AMP was  assayed  by  the  isolation of radiolabeled  cyclic 
AMP after incorporation of adenine-14C  into the tissues (6, 7) or by the cyclic AMP binding 
protein assay as described by Gilman  (8).  In the radioincorporation technique  (7),  200-rag 
replicates of human lung tissue were incubated with adenine-14C  for 2 hr at 37°C, washed ex- 
tensively to remove excess  adenine-14C,  incubated with the agent(s)  under study for 3  min 
(unless  stated otherwise in the text), and rapidly transferred to iced distilled water and boiled 
in order to liberate intracellular  14C-labeled nucleotides. The radiolabeled cyclic AMP was 
isolated  by  cation  exchange  chromatography  and  subsequent  paper  chromatography  and 
quantitated by liquid scintillation counting. 
For  the  assay  utilizing  the  cyclic AMP  binding  protein  isolated  from  bovine  skeletal 
muscle  (9),  200-mg  replicates of lung  tissue,  after incubation  in Tyrode's buffer with any 
agent(s)  under  study,  were  transferred  to  1.0 ml iced 5%  trichloroacetic acid  (TCA)  and 
boiled for 30 rain.  The  lung fragments  were  then homogenized by hand  in a  Ten  Broeck 
Homogenizer (Fisher Scientific Co., Pittsburgh,  Pa.),  centrifuged at 6000 g for 20 rain,  and 
the supernatant  decanted.  0.1  ml of 1 N HCI was  added  to  the supernatant  and  the TCA 
extracted  three times with 5 volumes each of water-saturated  ethyl ether  (Fisher Scientific 
Co.). The supernatant  was evaporated to dryness,  resuspended  in 0.5  ml acetate buffer  (50 
mM, pH 4.0),  and a sample of 10-100 #1 (depending upon the experimental design)  was added 
to assay tubes containing 0.5 pmoles of ~H-labeled cyclic AMP, 50/zg of bovine serum albumin 
in acetate buffer (50 raM, pH 4.0), and 50/~g of cyclic AMP binding protein in that order to a 
total final volume of 250 bd. After incubation of the mixture for 60 min at 0°C, the volume 558  ENI-IANCEMENT OF  MEDIATOR  RELEASE 
was brought to 1 ml with iced potassium phosphate buffer (20 raM, pH 6.0),  and 5 rain later 
the mixture was filtered through cellulose  ester filter previously soaked with the potassium 
phosphate buffer and subsequently washed with 10 ml of the same buffer (8). The filter was 
placed in chilled Bray's solution for 12 hr and counted in a Nuclear-Chicago Mark I  liquid 
scintillation counter  (Nuclear-Chicago, Des Plaines, Ill.). The blank in the absence of bind- 
ing protein was 20-30 cpm. In each experiment the amount of cyclic AMP in the lung tissue 
replicate bound  to the binding protein was determined by comparison with the per cent in- 
hibition of binding of the 3H-labeled cyclic AMP in a standard curve of 2-25 pmoles of cyclic 
AMP run simultaneously. Human lung tissue was found to contain from 167  to 825 pmoles 
cyclic AMP/g wet weight (ww) with a mean of 417 pmoles/g ww in eight experiments. 
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FIG.  1.  The  effect of norepinephrine with and without propranotol  on  the immunologic 
release of histamine and SRS-A from human lung tissue along with the concomitant changes 
in the tissue levels of cyclic AMP. Propranolol was added  to the incubation medium 1 min 
before  the  introduction  of  norepinephrine  and  the replicate  tissues  were either challenged 
with antigen  or assayed for cyclic AMP 2  min later.  In this experiment,  cyclic AMP was 
assayed by the cyclic AMP binding protein technique. 
RESULTS 
Alpha Adrenergic Stimulation.--The  effect  of  the  catecholamine  norepi- 
nephrine with and  without  the beta adrenergic  blocking agent proporanolol  on 
the immunologic release of histamine and  SRS-A as well as on the tissue  levels 
of  cyclic AMP  is  demonstrated  in  Fig.  1.  Norepinephrine  (10  -5 M)  produced 
an  increase of 94%  in  the  cyclic AMP  levels, from  198  pmoles in  the  controls 
to  385  pmoles/g ww in  the  drug-treated  samples,  and  total  suppression  of the MICHAEL KALINER~ ROBERT P.  ORANGE. K.  FRANK AUSTEN  559 
release of both mediators.  Propranolol  (10-  6 M), which by itself had no effect 
on either cyclic AMP levels or mediator release, prevented the norepinephrine- 
induced increase in cyclic AMP levels and lowered the inhibition  of mediator 
release  to  less  than  50%.  A  lesser concentration  of norepinephrine  (10-  6 ~) 
increased cyclic AMP by 28 %  and significantly inhibited  the antigen-induced 
release  of  mediators.  The  introduction  of  an  equimolar  concentration  of 
propranolol (10-  G  ~r) resulted in a 25 % decrease in the level of cyclic AMP and 
an enhancement of histamine release of 11%  and of SRS-A release of 100%. 
In eight additional experiments using equimolar concentrations of norepineph- 
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FIG. 2. The effect of phenylephrine with and without  propranolol on the immunologic 
release of histamine and SRS-A from human lung tissue along with the concomitant changes 
in the tissue levels of cyclic  AMP. The same protocol as outlined in Fig. I was used and cyclic 
AMP was assayed by the cyclic AMP binding protein technique. 
rine and propranolol (10  -6 •),  the mean average decrease in cyclic AMP levels 
was  32%  (range  of  decrease  17-68%)  while  the  mean  enhancement  of  the 
release of histamine and SRS-A was 30 %  (range of increase 7-40 %)  and 97 % 
(range of increase 40-180%),  respectively. 
The capacity of the relatively specific alpha adrenergic agent phenylephrine 
to decrease cyclic AMP levels and enhance mediator release with and without 
the  introduction  of a  beta adrenergic  blocking agent is illustrated  in  Fig.  2. 
Phenylephrine alone, in concentrations ranging from 10--  ~ to 10-  9 ~r, decreased 
the  levels  of  cyclic  AMP  while  enhancing  the  antigen-induced  release  of 
histamine and  SRS-A in  a  nondose-related fashion.  The introduction  of pro- 560  ENHANCEMENT  OF MEDL4.TOR  RELEASE 
pranolol (10  -6 M) uncovered a dose-response effect of phenylephrine in enhanc- 
ing mediator release without  further depleting  the  levels of cyclic AMP.  In 
five experiments, phenylephrine  (10  .8 M)  produced a mean depletion of cyclic 
AMP of 32 %  (range of decrease 25-41%) while the mean enhancement in the 
release of histamine was 48%  (range of increase  14-70%)  and of SRS-A was 
6t%  (range of increase 33-108%). 
Cholinergic Stirnulation.--The  effect of  the  cholinergic  agent  acetylcholine 
(10--7-10 -11 M)  on  the immunologic release of mediators  and  the  tissue levels 
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Fro.  3.  The effect of acetylcholine on  the immunologic release of histamine and  SRS-A 
from human lung  tissue along with the concomitant changes in  the tissue levels of cyclic 
AMP.  Lung  tissue was  incubated  with  varying  concentrations of acetylcholine for 3  rain 
before either antigen challenge or cyclic AMP assay by the cyclic AMP binding protein tech- 
nique. 
of cyclic  AMP is presented in Fig.  3. Enhancement  of histamine release was 
observed with acetylchotine in concentrations of  10-r-10  -1° M while  enhance- 
ment of SRS-A release was evident at all concentrations of acetylcholine tested 
with a  peak effect at  10  --9 M. The levels of cyclic AMP showed no consistent 
pattern. 
Because  of its  resistance  to  hydrolysis  by acetylcholinesterase,  carbamyt- 
choline  chloride  (Carbachol)  was  employed  in  all  subsequent  experiments. 
Carbachot  (10-El0  -1~ M)  was  found  to  result  in  enhancement  of  the  IgE- 
mediated release of both histamine and SRS-A at all concentrations with  the 
maximal  effect seen  at  10  -1° M Carbachol  (Fig.  4).  Cyclic AMP  levels were 
again found  to bear  no  consistent  relationship with  mediator  release.  In  16 MICHAEL  KALINER~  ROBERT P.  ORANGE, K.  FRANK  AUSTEN  561 
experiments utilizing  10.  ~° M Carbachol,  the  mean  enhancement  of  the  im- 
munologic release of histamine  was 44%  (range of increase 8-181%)  and  of 
SRS-A,  110%  (range of increase 23-270%), while the mean change in  cyclic 
AMP levels was less than 1% from control (range of change +32 to --14%). 
The  antigen-induced release  of  chemical  mediators  at  various  times  after 
cholinergic stimulation with  Carbachol  (10.  ~° M)  is illustrated in  Fig.  5.  En- 
hancement of mediator release was evident at 1 rain and reached a peak effect 
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FIG. 4.  The effect of Carbachol on the immunologic release of histamine and SRS-A from 
human lung tissue along with the concomitant changes in the tissue levels of cyclic AMP. 
The same protocol as outlined for Fig. 3 was used and cyclic AMP was assayed by the radio- 
incorporation and subsequent isolation of 14C-labeled cyclic AMP technique. 
within  5  nfin while  the level of cyclic AMP  was unchanged  throughout the 
experiment. 
Preincubating  the  tissues  with  the  antimuscarinic  agent  atropine  sulfate 
(10-~-10.1° M)  for 1 rain before the addition of Carbachol  (10  -1° M)  revealed 
that in concentrations of 10.  8 M or more the agent completely prevented the 
Carbachol-induced enhancement of mediator release, while at  concentrations 
of 10.  9 M or less it had no effect (Table I). In the doses used,  atropine itself 
had no influence upon mediator release. 
The capacity of atropine (10.  s M) to inhibit cholinergic enhancement but not 
alpha adrenergic enhancement is illustrated in Fig. 6. Atropine (10.  8 M)  pre- 562  ENIIANCEMENT  OF  MEDIATOR  RELEASE 
vented  the  Carbachol-stimulated  enhancement,  had  no  effect on the phenyl- 
ephrine-induced  enhancement,  and when used in  the presence of both  agents 
reduced the enhancement to that observed with phenylephrine alone. 
Effects  of Cyclic  GMP.--The  knowledge  that  cholinergic  stimulation  in- 
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FI6.  5. The effect of varying the time of preincubation with Carbachol  (10  -:° ~) on the 
immunologic release of histamine  and SRS-A from human lung  tissue along with the con- 
comitant changes in the tissue levels of cyclic AMP. Lung tissue was incubated with Carbachol 
for 1-15 min before either antigen challenge or cyclic AMP assay by the radioincorporation 
and subsequent isolation of 14C-labeled cyclic AMP technique. 
TABLE  I 
Prevention by Atropine  of the  Carbachol-Induced Enhancement of  the  Immunologic Rdease 
of Histamine and SRS-A from Human Lung Tissue 
Agonist  Antagonist  Histamine (change)  SRS-A  (change) 
%  % 
Carbachol  +23  +54 
10  -10 M 
Carbachol  Atropine  -- 11  -- 8 
10  -:0 ~  10  -~ 
Carbachol  Atropine  -- 7  -- 20 
I0  -i° ~  lO  s 
Carbachol  Atropine  +40  +35 
10  -1° ~  10  -9 ~a 
Carbachol  Atropine  +21  +54 
10  -10 M  10  -1° M 
creases the tissue levels of cyclic GMP  (10-12)  prompted a  study of the direct 
effect  of  cyclic GMP  on  the  immunologic  release  of  chemical  mediators.  8- 
bromo-cyclic GMP produced a dose-response enhancement of the immunologic 
release of both histamine and SRS-A (Fig. 7). The enhancing effect of 8-bromo- ~  160 
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FIo.  6.  The effect of atropine on cholinergic and alpha adrenergic-induced enhancement 
of the immunologic release of histamine and SRS-A from human lung tissue. Atropine was 
added to the incubation medium i  min before the addition of Carbachol, phenylephrine, or 
both. Antigen was added 3 min after the agonists. 
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FIG.  7.  The effect of 8-bromo-cyclic GMP on the immunologic release of histamine and 
SRS-A from human lung tissue. Varying concentrations of 8-bromo-cyelic GMP were added 
to the incubation medium 5 rain before antigen challenge. 
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cyclic GMP  (10- s ~[)  was most evident after  1-5  rain  and the effect fell off 
after 15 rain. Previous studies with dibutyryl cyclic AMP had revealed a dose- 
response  inhibition of mediator release  (3).  A  comparison of  the  effects  of 
8-bromo-cyclic GMP (10  -6 ~I) and dibutyryl cyclic AMP (10  -~ M) introduced 
5  rain  before the  antigen-induced release  of chemical mediators is  shown in 
Fig.  8.  While  8-bromo-cyclic  GMP  produced  a  marked  enhancement,  the 
dibutyryl  derivative  of  cyclic  AMP  inhibited  the  immunologic  release  of 
histamine and SRS-A. 
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[FIG.  8.  Comparison of the effects of 8-bromo-cyclic GMP and  dibutyryl cyclic AMP on 
the immunologic release of histamine and SRS-A from human lung tissue. The same protocol 
as outlined for Fig. 7 was used. 
DISCUSSION 
The IgE-mediated release of histamine and SRS-A from human lung tissue 
is  enhanced by both  alpha adrenergic  and  cholinergic stimulation. Previous 
studies  have  revealed  that  agents  increasing  cellular levels  of  cyclic AMP, 
such as beta adrenergic stimulants or methylxanthines, suppress the immuno- 
logic release of these mediators. Beta adrenergic blockade of lung tissue sub- 
sequently  stimulated  with  catecholamines  such  as  epinephrine  or  norepi- 
nephrine (Fig. 1) which possess both alpha and beta adrenergic activity results 
in decreases in tissue levels of cyclic AMP and enhancement of the release of 
mediators  (3,  5).  Further  documentation  of  the  relationship  of  enhanced 
mediator  release  and  alpha  adrenergic  stimulation  was  achieved  using  the 
relatively  specific  alpha  adrenergic  agent  phenylephrine  (Fig.  2).  Although 
this a~ent alone enhanced the immunologic release of chemical mediators, beta MICHAEL  KALINER,  ROBERT  P.  ORANGE,  K.  FRANK  AUSTEN  565 
adrenergic blockade increased its ability and uncovered a dose-response effect. 
The dose-response enhancement of mediator release by phenylephrine in the 
presence of propranolol was not associated with a  greater depletion of cyclic 
AMP  levels  than  observed  with  phenylephrine  alone.  This  discrepancy  is 
attributed to the fact that the level of cyclic AMP relates to the heterogeneous 
cell population constituting the entire lung fragment, while mediator release 
involves a  discrete subpopulation  of target  cells.  The  consistent qualitative 
relationship  between  the  alpha  adrenergic  enhancement of mediator release 
and the decrease in total tissue cyclic AMP was observed whether cyclic AMP 
was measured by methods based upon the isolation of radiolabeled cyclic AMP 
after  incorporation  of  adenine-14C  into  the  tissue  (7)  or  by  a  cyclic AMP 
binding  protein  assay  (8).  In  eight  experiments  studying alpha  adrenergic 
stimulation as achieved by combining equimolar concentrations  (10  -6 M)  of 
norepinephrine and propranolol (Fig. 1), the mean decrease in cyclic AMP was 
32 %,  while the mean enhancement of the inmmnologic release of histamine 
was 30% and of SRS-A was 97 %. In five experiments phenylephrine (10  -8 M) 
produced a  Inean decrease in the tissue levels of cyclic AMP of 32 %  and a 
mean increase in the release of histamine of 48% and of SRS-A of 64%. 
Cholinergic enhancement of the immunologic release of chemical mediators 
was observed with as little as 10-1° M acetylcholine (Fig. 3) or 10  -13 M Carbachol 
(Fig. 4). This enhancement was not associated with a consistent change in the 
levels of cyclic AMP (Figs. 3-5). In 16 experiments with Carbachol (10-  TM M), 
the mean change in cyclic AMP levels was less  than 1% while the mean en- 
hancement of  the  antigen-induced release  of histamine  and  SRS-A  was  44 
and 110%,  respectively. 
The finding that atropine prevents cholinergic enhancement but not com- 
parable alpha adrenergic enhancement is consistent with the view that adren- 
ergic and cholinergic agonists interact with separate receptor sites on the target 
cells  in  human lung tissue involved in  the  immunologic release  of chemical 
mediators (Fig. 6). That the adrenergic effects may be expressed through the 
levels of cyclic AMP is indicated by the consistent inverse association between 
the levels of cyclic AMP and mediator release plus the capacity of dibutyryl 
cyclic AMP to inhibit the release of mediators (Fig. 8)  (3).  That cholinergic 
enhancement may be mediated by cyclic GMP (Figs. 7 and 8) is suggested by 
the recent findings of others  that cholinergic stimulation of tissues increases 
the level of cyclic GMP  (10-12)  and by the demonstration herein that exog- 
enous 8-bromo-cyclic GMP enhances the immunologic release of histamine and 
SRS-A  in  a  dose-response  fashion.  Taken  together,  these  and  our previous 
studies (3, 5) suggest that the target cells in human lung tissue involved in the 
immunologic release of mediators possess  adrenergic and cholinergic receptor 
sites which when stimulated are capable of modulating a complex immunologic 
reaction through changes in the level of two cyclic nucleotides,  cyclic AMP 
and  cyclic  GMP. 566  ENHANCEMENT  OF  MED~TOR  RELEASE 
SUMMARY 
The immunologic release of histamine and  slow reacting substance of ana- 
phylaxis (SRS-A) from human lung tissue can be enhanced by stimulation with 
either alpha adrenergic agents (phenylephrine or norepinephrine in the presence 
of propranolol) or cholinergic agents (acetylcholine or Carbachol). The finding 
that  atropine prevents  cholinergic  but  not  comparable  alpha  adrenergic  en- 
hancement is consistent  with  the  view that  cholinergic  and  alpha  adrenergic 
agonists  interact with  separate receptor  sites on  the  target  cells involved in 
the  immunologic  release  of  chemical  mediators.  The  consistent  qualitative 
relationship  between  the  antigen-induced  release  of mediators  and  the  level 
of cyclic adenosine monophosphate (cyclic AMP)  as measured by the isolation 
of 14C-labeled  cyclic AMP after incorporation of adenineJ4C into the tissues or 
by the cyclic AMP binding protein assay suggests that changes in the level of 
this cyclic nucleotide mediate adrenergic modulation of the release of histamine 
and SRS-A. The addition  of 8-bromo-cyclic guanosine monophosphate (cyclic 
GMP) produces an enhancement of the immunologic release of mediators while 
dibutyryl cyclic AMP  is inhibitory.  As  cholinergic-induced  enhancement was 
not associated with a measurable change in the levels of cyclic AMP, the pos- 
sibility  is  suggested  that  cyclic  GMP  may be  the  intracellular  mediator  of 
cholinergic-induced enhancement of the immunologic release of histamine and 
SRS-A. 
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